Přejít k obsahu
Merck
Všechny fotografie(1)

Key Documents

208733

Sigma-Aldrich

Calpain Inhibitor Set

The Calpain Inhibitor Set controls the biological activity of Calpain. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.

Synonyma:

Calplain inhibitor

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen


About This Item

UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

form

solid

potency

8 nM Ki

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
desiccated
protect from light

shipped in

ambient

storage temp.

−20°C

General description

Calpains are a family of calcium-dependent thiol-proteases that act on a wide variety of cytoskeletal, membrane-associated, and regulatory proteins. There are two major isoforms: calpain I (µ-form) and calpain II (m-form), which differ in their calcium requirement for activation Calpains are composed of heterodimers of 80 kDa and a 30 kDa subunits. The 80 kDa unit has the catalytic site and is unique to each isozyme, whereas the 30 kDa unit is the regulatory subunit and is common to both µ- and m-isozymes.



More recently, attention has been focused on the pathological significance of calcium accumulation in the central nervous system following cerebral ischemia and traumatic brain injury. Over-activation of NMDA, kainate, and AMPA receptors in the brain leads to sustained influx of Ca2+ through the voltage-gated calcium channels. Overexpression of calpains has been positively linked to both acute and chronic neurodegenerative processes including ischemia, trauma, and Alzheimer′s disease. In Alzheimer′s disease the ratio of active (76 kDa) to inactive (80 kDa) µ-calpain is reported to be much higher Calpain-dependent proteolysis is usually the late-stage common pathway towards cell death induced by excitotoxic compounds, hence, a selective inhibition of calpains to limit neuronal damage appears to be a viable therapeutic measure.
Contains 5 mg of ALLN (Cat. No. 208719), 25 mg of Calpain Inhibitor III (Cat. No. 208722), 5 mg of Calpeptin (Cat. No. 03-34-0051), 1 mg of EST (Cat. No. 330005), and 5 mg of PD 150606 (Cat. No. 513022).

Biochem/physiol Actions

Cell permeable: yes
Primary Target
calpain 1, calpain 2
Reversible: no

Packaging

Packaged under inert gas

Warning

Toxicity: Multiple Toxicity Values, refer to MSDS (O)

Other Notes

Johnson, G.V.W., and Guttmann, R.P. 1997. BioEssays19, 1011.
Kampfl, A., et al. 1997. J. Neurotauma14, 121.
Sorimachi, H., et al., 1997. Biochem. J.328, 721.
Bartus, R.T., et al. 1995. Neurol. Res.17, 249.
Wang, K.K.W., and Yuen, P-W. 1994. Trends Pharmacol. Sci.15, 412.
Saito, K., et al. 1993. Proc. Natl. Acad. Sci. USA90, 2628.
Goll, D.E., et al. 1992. BioEssays14, 549.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

11 - Combustible Solids


Osvědčení o analýze (COA)

Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Zákazníci si také prohlíželi

Slide 1 of 3

1 of 3

PD 150606 ≥97% (HPLC)

Sigma-Aldrich

D5946

PD 150606

EST A cell-permeable, irreversible inhibitor of cysteine proteases.

Sigma-Aldrich

330005

EST

MDL 28170 ≥90% (TLC)

Sigma-Aldrich

M6690

MDL 28170

Pradoldej Sompol et al.
Aging cell, 20(7), e13416-e13416 (2021-06-13)
Inhibition of the protein phosphatase calcineurin (CN) ameliorates pathophysiologic and cognitive changes in aging rodents and mice with aging-related Alzheimer's disease (AD)-like pathology. However, concerns over adverse effects have slowed the transition of common CN-inhibiting drugs to the clinic for
Azizul Haque et al.
Experimental neurology, 330, 113315-113315 (2020-04-18)
Parkinson's disease (PD), a debilitating progressive degenerative movement disorder associated with loss of dopaminergic (DA) neurons in the substantia nigra (SN), afflicts approximately one million people in the U.S., including a significant number of Veterans. Disease characteristics include tremor, rigidity

Související obsah

Select different protease inhibitor types based on your needs to prevent protein degradation during isolation and characterization and safeguard proteins in sample prep.

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.